Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsOscar Health Autoimmune Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentOscar HealthPolicy N/A

    AUTOIMMUNE CONDITIONS EXCEPTIONS CRITERIA FOR CERTAIN STATES

    Customize your policy alerts

    Sign up for all Oscar Health policy alerts

    Know when Oscar Health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs preferred-product requirements and prior-authorization exceptions for targeted drugs used to treat specified autoimmune conditions. It applies to members in Florida, Georgia, Iowa, New Jersey, Ohio, Tennessee, and Texas, subject to other applicable utilization-management programs.

    Policy Summary
    PayerOscar Health
    PolicyAUTOIMMUNE CONDITIONS EXCEPTIONS CRITERIA FOR CERTAIN STATES
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage change
    Effective DateN/A
    Last ReviewAug 3, 2026
    Next Review DateN/A
    Key ActionEvaluate each targeted-product request under the member’s condition-specific exception criteria and submit prior-authorization documentation of required preferred-product failures, intolerance, or applicable exceptions.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    7Applicable states
    10Autoimmune indications addressed
    1Preferred infliximab product
    Prior authorizationException review mechanism

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    All preferred products
    General response or intolerance standard

    Targeted-Product Coverage Criteria

    Initial targeted-product exception criteria

    Coverage for a targeted product listed in Table 1 is provided when ONE of the following criteria is met:

    At least one applicable exception

    • Preferred-product failure or intolerance: The member has a documented inadequate response or intolerable adverse event with ALL of Cosentyx SC, Enbrel, Humira, Rinvoq, and tofacitinib IR/ER.ALL preferred products

      A documented clinical reason to avoid TNF inhibitors or JAK inhibitors may remove the corresponding class requirement.

    • Targeted adalimumab exception: The requested product is a targeted adalimumab product; the member has a documented intolerable adverse event to Humira that was not an expected adverse event attributed to the active ingredient; and the member has a documented inadequate response or intolerable adverse event with Cosentyx SC, Enbrel, Rinvoq, and tofacitinib IR/ER.Both conditions plus all applicable preferred products
    • Cimzia reproductive-status exception: The requested product is Cimzia and the member is currently breastfeeding, pregnant, or planning pregnancy.
    • Current-treatment exception: The requested product is Bimzelx, Cimzia, Simponi, or Taltz and the member is currently receiving treatment with the requested product.

      The product must not have been obtained as samples or through a manufacturer's patient-assistance program.

    General targeted-product exceptions

    Non-infliximab targeted products are covered when ONE of the following exception pathways is met:

    Applicable exception pathway

    • Preferred-product failure or intolerance: The member has a documented inadequate response or intolerable adverse event with the required preferred products for the diagnosis and requested product.ALL, BOTH, at least FIVE, or at least SIX, as applicable

      Documented clinical reasons to avoid TNF inhibitors or JAK inhibitors, and primary non-response to an IL-23 inhibitor where specified, may remove the corresponding class requirement.

    • Targeted adalimumab exception: The requested product is a targeted adalimumab product; the member had a qualifying intolerable adverse event to Humira; and the member had inadequate response or intolerance to the applicable remaining preferred products.
    • Targeted ustekinumab exception: The requested product is a targeted ustekinumab product; the member had a qualifying intolerable adverse event to the preferred ustekinumab product; and the member had inadequate response or intolerance to the applicable remaining preferred products.

    Ankylosing spondylitis

    Ankylosing spondylitis and the member meets ONE of the following criteria:

    Preferred-product failure or intolerance: The member has a documented inadequate response or intolerable adverse event with all applicable preferred products: Cosentyx SC, Enbrel, Humira, Rinvoq, and tofacitinib IR/ER.ALL preferred products

    A documented clinical reason to avoid the corresponding drug class may remove the applicable TNF-inhibitor or JAK-inhibitor trial requirement.

    Crohn's disease

    Crohn's disease and the member meets ONE of the following criteria:

    Crohn's disease exception pathway

    • Preferred-product pathway: The member has a documented inadequate response or intolerable adverse event with ALL of the applicable preferred products, including Humira, Rinvoq, Skyrizi IV/SC, Tremfya IV/SC, and Yesintek IV/SC, or the applicable alternate product list.ALL applicable products

      Clinical reasons to avoid TNF inhibitors or JAK inhibitors, or primary non-response to an IL-23 inhibitor where specified, may remove the corresponding class requirement.

    • Six-product pathway: The member has a documented inadequate response or intolerable adverse event with at least SIX of Cosentyx SC, Enbrel, Humira, Otezla/Otezla XR, Rinvoq, Skyrizi SC, tofacitinib IR/ER, Tremfya SC, and/or Yesintek SC.At least SIX preferred products
    • Targeted adalimumab or ustekinumab pathway:

    Plaque psoriasis

    Plaque psoriasis and the member meets ONE of the following criteria:

    Preferred-product failure or intolerance: The member has a documented inadequate response or intolerable adverse event with ALL of Humira, Otezla/Otezla XR, Skyrizi SC, Taltz, Tremfya SC, and Yesintek SC.ALL six preferred products

    A documented clinical reason to avoid TNF inhibitors may remove the corresponding class requirement.

    Psoriatic arthritis

    Psoriatic arthritis and the member meets ONE of the following criteria:

    Psoriatic arthritis exception pathway

    • At-least-five pathway: The member has a documented inadequate response or intolerable adverse event with at least FIVE applicable preferred products.At least FIVE preferred products

      The applicable list varies by requested product and may include Cosentyx SC, Enbrel, Humira, Otezla/Otezla XR, Rinvoq, Skyrizi SC, tofacitinib IR/ER, Tremfya SC, and Yesintek SC. Class-avoidance exceptions apply as specified.

    • General preferred-product pathway: The member has a documented inadequate response or intolerable adverse event with ALL of Enbrel, Humira, Kevzara, Rinvoq, and tofacitinib IR/ER.ALL preferred products

      Documented TNF- or JAK-inhibitor avoidance may remove the corresponding class requirement.

    Rheumatoid arthritis

    Rheumatoid arthritis and the member meets ONE of the following criteria:

    Rheumatoid arthritis exception pathway

    • Preferred-product pathway: The member has a documented inadequate response or intolerable adverse event with ALL of Humira, Rinvoq, Skyrizi IV/SC, Tremfya IV/SC, Xeljanz XR 22 mg, tofacitinib IR/ER except generic ER 22 mg, and Yesintek IV/SC.ALL preferred products

      TNF-, JAK-, or IL-23-avoidance or non-response exceptions apply as specified.

    • Xeljanz-specific requirement: The requested product is Xeljanz or Xeljanz XR and the member has also had a documented inadequate response or intolerable adverse event with any ONE TNF inhibitor.Any ONE TNF inhibitor

    Ulcerative colitis

    Ulcerative colitis and the member meets ONE of the following criteria:

    Ulcerative colitis exception pathway

    • Preferred-product pathway: The member has a documented inadequate response or intolerable adverse event with ALL of Humira, Rinvoq, Skyrizi IV/SC, Tremfya IV/SC, Xeljanz XR 22 mg, tofacitinib IR/ER except generic ER 22 mg, and Yesintek IV/SC.ALL preferred products

      TNF-, JAK-, or IL-23-avoidance or non-response exceptions apply as specified.

    • Targeted adalimumab or ustekinumab pathway: The requested product is targeted adalimumab or ustekinumab, with the applicable qualifying adverse event and the required remaining preferred-product failures or intolerances.
    • Product-specific pathway: The request is for Entyvio IV, Entyvio SC after Entyvio IV induction, Omvoh SC after Omvoh IV induction, or a listed product currently being received.

    Polyarticular juvenile idiopathic arthritis

    Polyarticular juvenile idiopathic arthritis and the member meets ONE of the following criteria:

    Polyarticular juvenile idiopathic arthritis exception pathway

    • Cosentyx and Humira pathway: The member has a documented inadequate response or intolerable adverse event with BOTH Cosentyx SC and Humira.BOTH preferred products

      A documented clinical reason to avoid TNF inhibitors may remove the corresponding requirement.

    • Alternative preferred-product pathway: The member has a documented inadequate response or intolerable adverse event with ALL of Cosentyx SC and Rinvoq.ALL preferred products

      Documented TNF- or JAK-inhibitor avoidance may remove the corresponding requirement.

    • Targeted adalimumab pathway:

    Hidradenitis suppurativa

    Hidradenitis suppurativa and the member meets ONE of the following criteria:

    Preferred-product failure or intolerance: The member has a documented inadequate response or intolerable adverse event with the applicable preferred products, Cosentyx SC and Humira.ALL applicable preferred products

    Uveitis

    Uveitis and the member meets the following criterion:

    Qualifying Humira adverse event: The member has had a documented intolerable adverse event to Humira, and the adverse event was not an expected adverse event attributed to the active ingredient as described in the prescribing information.

    Infliximab products—exception criteria

    For infliximab products listed in Table 2, coverage for a targeted product is provided when ONE of the following criteria is met:

    Qualifying infliximab exception

    • Avsola failure or intolerance: The member has a documented inadequate response or intolerable adverse event with Avsola, and the adverse event was not an expected adverse event attributed to the active ingredient.
    • Clinical reason Avsola cannot be used: The prescriber provides a documented clinical reason why Avsola cannot be used, such as severe hypersensitivity to specific inactive ingredients present in Avsola but not the requested product.
    • Risk of destabilization: The member is currently stable on the requested infliximab product and switching to Avsola would pose a significant risk of destabilizing the member's condition.

      Examples include secondary loss of response after switching or a complex disease state in which maintaining the current regimen is critical.

    The current-treatment exception does not apply when the requested product was obtained as samples or through a manufacturer’s patient-assistance program. Documentation must establish that the member is receiving the requested product through an eligible source.

    Products obtained as samples or through a manufacturer’s patient-assistance program are excluded from current-treatment exception coverage. This limitation applies across the condition-specific continuation pathways identified in the policy.

    Initial Exception Therapy

    Initial exception review

    Coverage for a targeted product is provided when ONE of the applicable exception criteria is met:

    At least one applicable exception: The member meets at least one applicable preferred-product failure, intolerance, clinical-avoidance, reproductive-status, or current-treatment criterion.At least one criterion

    Initial exception therapy

    Initial exception requests generally require documented failure or intolerance of the applicable preferred products.

    Required preferred-product history: The member has documented inadequate response or intolerable adverse event with the required preferred products for the diagnosis and requested product.ALL, BOTH, at least FIVE, at least SIX, or any ONE, as specified

    A recognized class-avoidance, reproductive-status, current-treatment, induction-transition, or other product-specific exception may apply.

    Continuation and Current-Treatment Exceptions

    Current-treatment exception

    Coverage may be provided when the member is currently receiving the requested product.

    Current treatment with selected targeted product: The requested product is Bimzelx, Cimzia, Simponi, or Taltz and the member is currently receiving treatment with that product.Currently receiving requested product

    The product must not have been obtained as samples or through a manufacturer's patient-assistance program.

    Infliximab continuation exceptions

    Continuation of a requested infliximab product is supported when ONE of the following exceptions is met:

    Infliximab continuation exception: The member is currently stable on the requested infliximab product and switching to Avsola would pose a significant risk of destabilizing the condition; OR the requested product is Zymfentra after induction with infliximab of any brand and the prescriber considers continued maintenance clinically appropriate.

    Preferred-Product Requirements

    StepRequirementException
    1Document inadequate response or an intolerable adverse event with all applicable preferred products before requesting a targeted product.A documented clinical reason to avoid TNF inhibitors or JAK inhibitors, or an indication-specific exception, may remove the corresponding class requirement.
    ConditionPreferred products to tryThreshold
    General autoimmune pathwaysCosentyx SC; Enbrel; Humira; Rinvoq; tofacitinib IR/ERALL applicable products
    Crohn's diseaseHumira; Rinvoq; Skyrizi IV/SC; Tremfya IV/SC; Yesintek IV/SCALL five preferred products
    Crohn's disease—alternate pathwayCosentyx SC; Enbrel; Humira; Otezla/Otezla XR; Rinvoq; Skyrizi SC; tofacitinib IR/ER; Tremfya SC; Yesintek SCAt least SIX products
    Psoriatic arthritisCosentyx SC; Enbrel; Humira; Otezla/Otezla XR; Rinvoq; Skyrizi SC; Tremfya SC; Yesintek SC; tofacitinib IR/ERAt least FIVE applicable products or ALL of the specified products, depending on pathway
    Rheumatoid arthritisEnbrel; Humira; Kevzara; Rinvoq; tofacitinib IR/ERALL applicable products
    Ulcerative colitisHumira; Rinvoq; Skyrizi IV/SC; Tremfya IV/SC; Xeljanz XR 22 mg; tofacitinib IR/ER except generic ER 22 mg; Yesintek IV/SCALL applicable products
    Polyarticular juvenile idiopathic arthritisCosentyx SC and Humira, or Cosentyx SC and Rinvoq, depending on pathwayBOTH or ALL of the specified products
    Ankylosing spondylitisCosentyx SC; Enbrel; Humira; Rinvoq; tofacitinib IR/ERALL applicable products
    Plaque psoriasisHumira; Otezla/Otezla XR; Skyrizi SC; Taltz; Tremfya SC; Yesintek SCALL applicable products
    Hidradenitis suppurativaCosentyx SC; HumiraCondition-specific threshold applies
    UveitisHumiraOne specified preferred product
    Requested product pathwayRequired adverse eventAdditional preferred-product requirement
    Targeted adalimumabIntolerable adverse event to Humira that was not an expected adverse event attributed to the active ingredient.Document inadequate response or intolerance to the remaining applicable preferred products; the threshold may be ALL or at least FIVE, depending on the condition and pathway.
    Targeted ustekinumabIntolerable adverse event to the preferred ustekinumab product—Yesintek IV/SC or Yesintek SC, as applicable—that was not an expected active-ingredient adverse event.Document inadequate response or intolerance to the remaining applicable preferred products; the threshold may be ALL or at least FIVE, depending on the condition and pathway.
    Class-avoidance substitutionThe adalimumab or ustekinumab adverse event must still meet the qualifying, non-expected adverse-event standard.A documented clinical reason to avoid TNF inhibitors or JAK inhibitors, or primary non-response to an IL-23 inhibitor where specified, may remove the corresponding product-class trial requirement.
    Exception pathwayDocumentation required
    Avsola inadequate response or intoleranceDocument inadequate response or an intolerable adverse event with Avsola (infliximab-axxq); the event must not be an expected adverse event attributed to the active ingredient.
    Avsola cannot be usedDocument a clinical reason Avsola cannot be used, such as severe hypersensitivity to specific inactive ingredients present in Avsola but not the requested product.
    Stable on requested infliximab productDocument that switching to Avsola would pose a significant risk of destabilizing the condition, such as prior secondary loss of response after switching or a complex disease state requiring the current regimen.
    Zymfentra maintenanceDocument induction with infliximab from any brand and that continued Zymfentra maintenance is clinically appropriate.
    Preferred-Product Failure Threshold
    ThresholdAt least FIVE preferred products
    ApplicationApplies to specified preferred-product pathways for targeted adalimumab or ustekinumab requests in psoriatic arthritis
    Required evidenceDocumented inadequate response or intolerable adverse event for the required preferred products
    Preferred-Product Failure Threshold
    ThresholdAt least SIX preferred products
    Applicable conditionCrohn's disease

    Prior Authorization and Documentation

    Prior Authorization

    Targeted-Product Exception Review

    Submit the targeted-product request for prior authorization and clinical exception review. Coverage is available only when at least one applicable exception pathway in this section is documented.

    • Identify the requested product, indication, applicable preferred products, and qualifying clinical exception.
    • Include relevant treatment history, response, adverse events, contraindications, reproductive status, or current-treatment documentation as applicable.
    Note

    Program Applicability

    Apply the program to all members requesting a targeted product for plaque psoriasis. For other indications, apply the program unless the criteria identify a prior-use exemption.

    • Use the indication-specific preferred and targeted products in Table 1 and Table 2.
    • Review every request under all applicable Plan utilization-management programs.

    Administration Route

    Billing Rule

    Follow the listed administration route

    Use the route specified for the product in the applicable product table. Products may be administered subcutaneously or intravenously as indicated.

    • IV means intravenous administration.
    • SC means subcutaneous administration.

    Preferred and Targeted Products

    Billing Rule

    Use preferred infliximab when appropriate

    Avsola (infliximab-axxq) is the preferred infliximab product across all indications. Inflectra, infliximab, Remicade, Renflexis, and Zymfentra are targeted products.

    Billing Rule

    Recognize preferred ustekinumab

    Yesintek IV/SC is identified as the preferred ustekinumab product in applicable condition-specific pathways.

    Billing Rule

    Apply the ustekinumab biosimilar pathway

    Ustekinumab biosimilars may qualify as requested products under current-treatment or induction-related exception pathways, depending on the condition and formulation. Verify the applicable pathway before submitting the request.

    Policy Overview

    This policy governs coverage of targeted biologic and immunomodulatory therapies for specified autoimmune conditions. It designates preferred products and permits coverage exceptions when preferred therapy is ineffective, not tolerated, clinically inappropriate, or another stated exception applies. The conditions addressed include inflammatory arthritis, psoriasis, inflammatory bowel disease, uveitis, hidradenitis suppurativa, and axial spondyloarthritis. Targeted-product requests are evaluated through the applicable prior-authorization exception pathway.

    Terms and Abbreviations

    Definitions
    AbbreviationIV
    MeaningIntravenous administration
    Policy useIV identifies products administered intravenously in the product tables
    Definitions
    AbbreviationSC
    MeaningSubcutaneous administration
    Policy useSC identifies products administered subcutaneously in the product tables
    Policy Summary
    PayerOscar Health
    PolicyAUTOIMMUNE CONDITIONS EXCEPTIONS CRITERIA FOR CERTAIN STATES
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage change
    Effective DateN/A
    Last ReviewAug 3, 2026
    Next Review DateN/A
    Key ActionEvaluate each targeted-product request under the member’s condition-specific exception criteria and submit prior-authorization documentation of required preferred-product failures, intolerance, or applicable exceptions.
    SourceLink
    On This Page
    Targeted-Product Coverage CriteriaInitial Exception TherapyContinuation and Current-Treatment ExceptionsPreferred-Product RequirementsPrior Authorization and DocumentationAdministration RoutePreferred and Targeted ProductsPolicy OverviewTerms and Abbreviations
  1. Product-specific exception: The request qualifies under a specified Cimzia reproductive-status, induction-transition, or current-treatment pathway.
  2. The requested product is a targeted adalimumab or ustekinumab product, with the applicable qualifying adverse event and the required remaining preferred-product failures or intolerances.
  3. Product-specific pathway: The request is for Cimzia under the reproductive-status exception, Entyvio SC after Entyvio IV induction, Omvoh SC after Omvoh IV induction, or a listed product currently being received.

    Current-treatment products must not have been obtained as samples or through manufacturer assistance.

  4. Targeted adalimumab or ustekinumab pathway: The requested product is targeted adalimumab or ustekinumab, with the applicable qualifying adverse event and the required remaining preferred-product failures or intolerances.
  5. Current-treatment pathway: The member is currently receiving Bimzelx, Cimzia, Orencia IV/SC/Orencia ClickJect, Simponi, an ustekinumab biosimilar SC, or Taltz, as applicable.

    The product must not have been obtained as samples or through manufacturer assistance.

  6. Cimzia reproductive-status pathway: The requested product is Cimzia and the member is currently breastfeeding, pregnant, or planning pregnancy.
  7. Current-treatment products must not have been obtained as samples or through manufacturer assistance.

  8. Cimzia reproductive-status pathway: The requested product is Cimzia and the member is currently breastfeeding, pregnant, or planning pregnancy.
  9. The requested product is a targeted adalimumab product; the member has a qualifying intolerable adverse event to Humira and inadequate response or intolerance to Cosentyx SC.
  10. Current-treatment pathway: The member is currently receiving Bimzelx, Cimzia, Taltz, Actemra IV/SC/Actemra ACTPen, Avtozma IV/SC, or Orencia IV/SC/Orencia ClickJect, as applicable.

    The product must not have been obtained as samples or through manufacturer assistance.

  11. Rinvoq pathway: The requested product is Rinvoq and the member has a documented inadequate response or intolerance to any ONE TNF inhibitor.Any ONE TNF inhibitor
  12. Cimzia reproductive-status pathway: The requested product is Cimzia and the member is currently breastfeeding, pregnant, or planning pregnancy.
  13. Zymfentra maintenance: The requested product is Zymfentra, the member has undergone induction with infliximab of any brand, and the prescriber deems continued Zymfentra maintenance clinically appropriate.

    Targeted infliximab exception

    For a targeted infliximab product, coverage is available when ONE qualifying exception to Avsola use is documented.

    Qualifying exception to Avsola: The member has a documented inadequate response or intolerable non-expected adverse event with Avsola; the prescriber documents a clinical reason Avsola cannot be used; the member is stable on the requested product and switching would pose a significant risk of destabilization; or the requested product is Zymfentra after induction with infliximab and continued maintenance is clinically appropriate.ONE of four alternatives
    ONE of two alternatives

    The stability pathway requires documentation of the risk from switching; the Zymfentra pathway requires prior infliximab induction.

    Required evidenceDocumented inadequate response or intolerable adverse event with at least six listed preferred products
    Preferred-Product Failure Threshold
    ThresholdALL or BOTH of the specified preferred products, as applicable
    ALL requirementThe applicable preferred products must have documented inadequate response or intolerable adverse events
    BOTH requirementCertain targeted adalimumab and ustekinumab pathways require both a qualifying adverse event and the specified preferred-product history
    Prior Authorization

    Table 1 Targeted Products

    For targeted products listed in Table 1, excluding infliximab products, document one applicable exception pathway before approving coverage.

    • The applicable pathway may be preferred-product failure or intolerance, a targeted-product exception, pregnancy or breastfeeding, current treatment, induction history, or another indication-specific criterion.
    • Infiximab products follow the separate exception pathway described below.
    Documentation Required

    Apply Condition-Specific Criteria

    Apply the criteria for the member's specific indication and requested product. The request must identify the diagnosis, requested product, applicable preferred-product pathway, and any required threshold.

    • Plaque psoriasis: use the applicable ALL-of-preferred-products criteria and targeted-product exceptions.
    • Crohn's disease: apply the specified ALL, SIX, or product-specific criteria, including induction and current-treatment pathways.
    • Psoriatic arthritis: apply the specified ALL or FIVE preferred-product criteria and product-specific exceptions.
    • Ulcerative colitis: apply the specified ALL, BOTH, or product-specific criteria, including Xeljanz and IL-23 requirements.
    • Polyarticular juvenile idiopathic arthritis: apply the specified ALL or BOTH preferred-product criteria and product-specific exceptions.
    Prior Authorization

    Infliximab Product Exception

    For an infliximab product listed in Table 2, document at least one qualifying exception to the preferred Avsola pathway.

    • Document inadequate response or an intolerable, non-expected adverse event with Avsola.
    • Alternatively, document why Avsola cannot be used, significant destabilization risk from switching while stable, or qualifying prior infliximab induction for Zymfentra maintenance.
    Step Therapy

    Preferred-Product Step Therapy

    Use preferred-product step therapy unless the member has documented inadequate response or intolerable adverse events with the applicable preferred products, or a recognized clinical reason to avoid the relevant drug class.

    • Document the product, dates or duration of use, clinical response, and adverse-event history.
    • A clinical reason to avoid TNF or JAK inhibitors may remove the corresponding preferred product requirement; primary non-response to an IL-23 inhibitor may remove applicable IL-23 requirements.
    Step Therapy

    Condition-Specific Step-Therapy Thresholds

    Apply the preferred-product list and threshold for the member's indication and requested product. Do not substitute a general failure history for the condition-specific requirement.

    • Some pathways require ALL listed products; others require BOTH, FIVE, or SIX products.
    • For targeted adalimumab, document Humira intolerance plus the applicable remaining preferred-product history.
    • For targeted ustekinumab, document intolerance to the preferred ustekinumab product plus the applicable preferred-product history.
    • For Xeljanz/Xeljanz XR in ulcerative colitis, document failure or intolerance to any ONE TNF inhibitor when required.
    Documentation Required

    Class-Avoidance Substitution

    A class-avoidance exception must be supported by documented clinical rationale. Avoidance of TNF or JAK inhibitors removes only the corresponding preferred-product requirements; applicable IL-23 requirements remain unless the policy permits an IL-23 primary non-responder exception.

    • TNF avoidance examples: demyelinating disorder, congestive heart failure, hepatitis B infection, autoantibody formation or lupus-like syndrome, malignancy risk, or primary TNF non-response.
    • JAK avoidance examples: malignancy risk, major adverse cardiovascular event risk, thrombotic-event risk, hepatitis B or C infection, or primary JAK non-response.
    • For applicable Crohn's disease, psoriasis, or ulcerative-colitis pathways, document primary non-response to an IL-23 inhibitor when relying on that exception.
    Step Therapy

    Avsola Exception Pathway

    For infliximab products, Avsola is the preferred product unless the prescriber documents a qualifying exception.

    • Document inadequate response or an intolerable, non-expected adverse event to Avsola; or
    • Document a clinical reason Avsola cannot be used, such as severe hypersensitivity to an inactive ingredient present in Avsola but not the requested product; or
    • Document stability on the requested infliximab product and significant risk of destabilization from switching.
    Documentation Required

    Preferred-Product Trial Documentation

    Submit complete documentation of the preferred-product trials supporting the exception, including inadequate response or intolerable adverse events for each product required by the applicable indication.

    • Include product name, treatment dates or duration, dose when relevant, response or reason for discontinuation, and the prescriber's clinical rationale.
    • Document any class-avoidance exception used to waive a corresponding preferred product.
    Documentation Required

    Targeted Adalimumab Documentation

    For a targeted adalimumab request, document an intolerable adverse event to Humira that was not an expected adverse event attributable to the active ingredient.

    • Identify the Humira event, severity, timing, management, and outcome.
    • The event must be non-expected under prescribing information and must not merely be a known active-ingredient reaction shared by reference and biosimilar products.
    Documentation Required

    Current-Treatment Documentation

    For Bimzelx, Cimzia, Simponi, or Taltz pathways, document that the member is actively receiving the requested product when the indication-specific criteria allow current treatment.

    • State the product, current dose or regimen, and treatment start or continuation date.
    • Do not rely on current use obtained through samples or a manufacturer's patient assistance program.
    Documentation Required

    Pregnancy or Breastfeeding Documentation

    For a Cimzia pregnancy-related exception, document that the member is currently breastfeeding, pregnant, or planning pregnancy.

    • Record the applicable reproductive status and relevant timing or clinical context.
    • Use this exception only where Cimzia is the requested product and the indication-specific criteria permit it.
    Documentation Required

    Exception Clinical History

    The exception submission must connect the requested product and diagnosis to the applicable preferred-product history and clinical rationale.

    • Identify the requested product and indication.
    • List every required preferred product and whether the member had inadequate response, intolerable adverse event, or an approved class-avoidance exception.
    • Explain why the requested product is clinically appropriate.
    Denial Risk

    Adalimumab Exception Standard

    A targeted adalimumab exception requires both a qualifying Humira event and the applicable preferred-product history. The Humira event must be intolerable and non-expected.

    • Document the intolerable Humira adverse event and why it is not an expected active-ingredient reaction.
    • Document failure or intolerance with all, five, or the specifically listed preferred products required for the member's indication, subject to permitted class-avoidance exceptions.
    Documentation Required

    Ustekinumab Exception Standard

    A targeted ustekinumab exception requires a documented intolerable adverse event to the preferred ustekinumab product and the applicable preferred-product history.

    • Preferred ustekinumab product: Yesintek IV/SC or Yesintek SC, depending on indication.
    • The adverse event must be non-expected under prescribing information and not merely an expected active-ingredient reaction.
    • Also document the required ALL or FIVE preferred-product failures or intolerances, subject to permitted class-avoidance exceptions.
    Documentation Required

    Reproductive-Status Exception

    For a Cimzia reproductive-status exception, document that the member is currently breastfeeding, pregnant, or planning pregnancy.

    • This exception applies only when Cimzia is the requested product and the relevant indication-specific pathway includes the reproductive-status criterion.
    • Document the member's status in the clinical record and prior-authorization submission.
    Documentation Required

    Current-Treatment Verification

    Verify active receipt of the requested product when coverage is requested under a current-treatment exception.

    • Confirm the product and current regimen through an administration record, dispensing history, or other reliable clinical documentation.
    • Samples and manufacturer patient-assistance programs do not qualify as covered current treatment for this exception.
    Documentation Required

    Induction Treatment History

    For applicable subcutaneous products, document the required intravenous induction treatment before approving the subcutaneous maintenance product.

    • Entyvio SC requires prior Entyvio IV induction.
    • Omvoh SC requires prior Omvoh IV induction.
    • Zymfentra requires induction with infliximab, any brand, before clinically appropriate maintenance continuation.
    Documentation Required

    Avsola Exception Documentation

    For Avsola exceptions, document either inadequate response or an intolerable adverse event, and establish that the adverse event was not an expected active-ingredient reaction.

    • Include the Avsola treatment history, response, adverse-event details, and clinical outcome.
    • If the exception is based on inability to use Avsola or switching risk, provide the specific prescriber rationale and supporting history.
    Documentation Required

    Clinical Avoidance Rationale

    When waiving TNF- or JAK-inhibitor step therapy, document the applicable clinical reason to avoid the class.

    • TNF-inhibitor reasons include demyelinating disease, congestive heart failure, hepatitis B, lupus-like syndrome or autoantibody formation, malignancy risk, or primary TNF non-response.
    • JAK-inhibitor reasons include malignancy risk, major cardiovascular-event risk, thrombotic-event risk, hepatitis B or C, or primary JAK non-response.
    Denial Risk

    Insufficient Preferred-Product History

    Requests may be denied when the required preferred-product history is absent or insufficient. A general statement that prior therapy failed does not establish the applicable exception.

    • Document every required product and whether the outcome was inadequate response or intolerable adverse event.
    • Document treatment duration or dates, objective response when available, and the reason a product was stopped.
    • Use a class-avoidance or other stated exception only when the required clinical rationale is documented.
    Denial Risk

    Expected Active-Ingredient Adverse Event

    An expected adverse event attributed to the active ingredient does not qualify for the targeted adalimumab or targeted ustekinumab exception.

    • The event must be intolerable and not an expected reaction described in prescribing information.
    • The exclusion applies to known active-ingredient reactions for both reference and biosimilar products.
    Denial Risk

    Excluded Source of Current Therapy

    Current treatment does not qualify when the requested product was obtained only through samples or a manufacturer's patient-assistance program.

    • Verify active, covered treatment through claims, dispensing, administration, or other reliable records.
    • Apply this exclusion to current-treatment pathways across the indications and products listed in the policy.
    Denial Risk

    Condition-Specific Threshold Not Met

    A request may be denied when the indication-specific numerical or logical threshold is not met.

    • Apply the exact requirement: ALL, BOTH, FIVE, SIX, or any other stated threshold.
    • Examples include at least SIX preferred products for the applicable Crohn's disease pathway, at least FIVE for the applicable psoriatic-arthritis pathways, and BOTH or ALL where specified for ulcerative colitis or polyarticular juvenile idiopathic arthritis.
    • Confirm all product-specific requirements, including induction history and additional TNF-inhibitor requirements.
    Prior Authorization

    Required Infliximab Exception Pathway

    For infliximab products, coverage requires a qualifying exception to Avsola or the applicable Zymfentra induction pathway.

    • Qualifying exceptions include Avsola inadequate response or intolerable non-expected adverse event; documented inability to use Avsola; significant risk of destabilization from switching while stable; or infliximab induction before Zymfentra maintenance.
    • Document the prescriber's rationale and supporting clinical history.
    Billing Rule

    Support targeted infliximab use

    A targeted infliximab product requires a qualifying exception involving Avsola: inadequate response or intolerable non-expected adverse event, inability to use Avsola for a documented clinical reason, significant destabilization risk from switching, or the Zymfentra post-induction exception.

    Definitions
    Preferred productA medication designated formulary or preferred on the plan
    Prior authorizationA preferred product may still require clinical prior authorization review
    Coverage reviewTargeted-product coverage is reviewed based on clinical circumstances and applicable utilization-management programs
    Definitions
    Clinical reason to avoidA documented clinical reason to avoid a drug class
    Effect on step therapyThe corresponding preferred products from that class may be omitted from the trial requirement
    Classes identifiedTNF inhibitors and JAK inhibitors; primary non-response to an IL-23 inhibitor may also apply where specified
    Definitions
    Qualifying eventAn intolerable adverse event
    Expected-event exclusionThe event must not be an expected adverse event attributed to the active ingredient as described in prescribing information
    Reference and biosimilar productsThe definition includes a known reaction applicable to both reference and biosimilar products
    Definitions
    MeaningThe requested infliximab product is clinically appropriate to continue
    Switching concernSwitching to Avsola could significantly destabilize the member's condition
    ExamplesA history of secondary loss of response after switching or a complex disease state where maintaining the current regimen is critical
    Definitions
    Maintenance productZymfentra
    Prior treatmentInduction with infliximab from any brand
    Continuation requirementThe prescriber deems continued Zymfentra maintenance therapy clinically appropriate